Application Nr Approved Date Route Status External Links
ANDA204779 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications Lithium Carbonate Extended-Release Tablet Is Indicated In The Treatment Of Manic Episodes Of Bipolar Disorder. Bipolar Disorder, Manic (Dsm-Iv) Is Equivalent To Manic Depressive Illness, Manic, In The Older Dsm-Ii Terminology. Lithium Carbonate Extended-Release Tablet Is Also Indicated As A Maintenance Treatment For Individuals With A Diagnosis Of Bipolar Disorder. Maintenance Therapy Reduces The Frequency Of Manic Episodes And Diminishes The Intensity Of Those Episodes Which May Occur. Typical Symptoms Of Mania Include Pressure Of Speech, Motor Hyperactivity, Reduced Need For Sleep, Flight Of Ideas, Grandiosity, Elation, Poor Judgment, Aggressiveness, And Possibly Hostility. When Given To A Patient Experiencing A Manic Episode, Lithium May Produce A Normalization Of Symptomatology Within 1 To 3 Weeks.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Lithium Carbonate LITHIUM CARBONATE ZINC895081

Comments